Clinical Trial

Safety and Efficacy Study of TX103 CAR-T Cell Therapy for Recurrent or Progressive Grade 4 Glioma.

Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
This is a phase I, open-Label, single/multiple dose, dose-escalation study to evaluate the safety, tolerability and antitumor activity of anti-B7-H3 CAR-T cell injection (TX103) in subjects with recurrent or progressive Grade 4 Glioma.The study also plan to explore the Maximum Tolerated Dose (MTD) and determine the Recommended Phase II Dose (RP2D) of the CAR-T cell therapy.
Protocol Amendment History 4 amendments
This ClinicalTrials.gov record has been amended 4 times since 2024-06-25; most recent amendment 2026-03-19.
Status change: Not Yet Recruiting → Recruiting 2025-01-06
Trial Details
NCT Number NCT06482905
Lead Sponsor Tcelltech Inc.
Collaborators: Beijing Tiantan Hospital, Mayo Clinic
Conditions High-grade Glioma, WHO Grade Ⅳ Glioma
Enrollment 52 participants
Start Date 2024-09-04
Primary Completion 2026-09 (estimated)
Study Completion 2027-06 (estimated)
Updated on ClinicalTrials.gov 2026-03-24